Dragonfly Therapeutics présentera les résultats de la phase 1 de la monothérapie DF1001 à l’occasion du congrès annuel de l’ASCO 2023

Posted on by

Une présentation orale intitulée « Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results » sera présentée par Howard Safran, directeur médical, lors de la session ASCO…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.